Veradermics, Incorporated (MANE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Veradermics, Incorporated (MANE) Healthcare & Pipeline Overview

Veradermics, Incorporated, founded in 2019, is a biopharmaceutical company developing innovative dermatological and aesthetic treatments. Their pipeline focuses on addressing prevalent conditions like pattern hair loss and skin diseases, positioning them in the competitive biotechnology sector with a focus on unmet needs in dermatology.

What Is the Investment Thesis for MANE?

Veradermics, Incorporated presents a notable research candidate within the biotechnology sector, driven by its focus on dermatological and aesthetic conditions with significant unmet needs. The company's lead product, VDPHL01, targeting pattern hair loss, has the potential to capture a substantial market share. The development of VDMN, VDAA, and VDMC further diversifies the company's pipeline and reduces risk. However, the company's P/E ratio of -401.33 indicates it is not currently profitable. Key value drivers include successful clinical trials, regulatory approvals, and commercialization of its products. Upcoming clinical trial results for VDPHL01 will be a critical catalyst. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the dermatology market.

Based on FMP financials and quantitative analysis

MANE Key Highlights

Veradermics, Incorporated focuses on novel therapeutics for dermatologic and aesthetic conditions.

• The company's lead product, VDPHL01, is an oral, non-hormonal treatment for pattern hair loss.
• Veradermics is developing VDMN, a dissolvable microarray patch technology for immunotherapy of common warts.
• The company's pipeline includes VDAA for the treatment of alopecia areata and VDMC for molluscum contagiosum.
• Veradermics' P/E ratio is -401.33, reflecting its current lack of profitability as it invests in R&D.

Who Are MANE's Competitors?

MANE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MANE's Key Strengths?

Novel drug candidates targeting unmet needs in dermatology.

• Innovative drug delivery technologies (e.g., microarray patch).
• Experienced management team with expertise in drug development.
• Strong intellectual property portfolio.

What Are MANE's Weaknesses?

Limited commercialization experience.

• Dependence on successful clinical trial outcomes.
• High research and development costs.
• Currently unprofitable with a negative P/E ratio.

What Could Drive MANE Stock Higher?

Clinical trial results for VDPHL01 in pattern hair loss are expected in Q4 2026.

• Regulatory submissions for VDMN for the treatment of common warts are planned for H1 2027.
• Expansion of the company's research and development pipeline.
• Strategic partnerships with pharmaceutical companies.

What Are the Key Risks for MANE?

Negative return on equity (-95.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for any of the company's drug candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies with greater resources.
• High research and development costs.
• Dependence on securing additional funding to support operations.

What Are the Growth Opportunities for MANE?

• Expansion into new therapeutic areas represents a significant growth opportunity for Veradermics. By leveraging its expertise in dermatological drug development, the company can explore treatments for other skin conditions, such as psoriasis, eczema, and skin cancer. The global market for psoriasis treatment alone is projected to reach $25 billion by 2028, offering a substantial revenue opportunity. This expansion would require further investment in research and development, but could significantly diversify the company's product portfolio and revenue streams.
• Geographic expansion into international markets presents another key growth opportunity. While Veradermics is currently based in the United States, the company can expand its reach by commercializing its products in Europe, Asia, and other regions. The global dermatology market is experiencing rapid growth, particularly in emerging economies, driven by increasing disposable incomes and a growing awareness of skin health. Entering these markets would require navigating different regulatory landscapes and establishing local partnerships, but could significantly increase the company's sales and profitability.
• Strategic partnerships and collaborations with other pharmaceutical companies and research institutions can accelerate the development and commercialization of Veradermics' products. By partnering with larger companies, Veradermics can gain access to additional resources, expertise, and distribution networks. These partnerships can also help to reduce the financial risk associated with drug development and increase the likelihood of regulatory approval. The biotechnology industry is characterized by a high degree of collaboration, and Veradermics can benefit from actively seeking out strategic alliances.
• Development of novel drug delivery systems can enhance the efficacy and patient compliance of Veradermics' products. The company's VDMN dissolvable microarray patch technology represents a promising approach to drug delivery, offering a non-invasive and convenient alternative to traditional injections. By continuing to invest in innovative drug delivery systems, Veradermics can differentiate its products from competitors and improve patient outcomes. The market for drug delivery systems is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and patient-centric healthcare.
• Targeting pediatric dermatological conditions represents a largely untapped market with significant growth potential. Many skin conditions, such as atopic dermatitis and molluscum contagiosum, are common in children, but there are limited treatment options available. By developing safe and effective therapies specifically for pediatric patients, Veradermics can address a significant unmet need and capture a substantial share of this market. This would require conducting clinical trials in pediatric populations and obtaining regulatory approval for pediatric use, but could significantly expand the company's reach and impact.

What Are MANE's Competitive Advantages?

• Proprietary drug formulations and delivery systems.
• Patent protection for novel therapeutics.
• Clinical data supporting efficacy and safety.
• Established relationships with key opinion leaders in dermatology.

What Does MANE Do?

Veradermics, Incorporated, established in 2019 and headquartered in New Haven, Connecticut, is a biopharmaceutical company dedicated to the discovery and development of novel therapies for dermatologic and aesthetic conditions. The company's core focus lies in addressing unmet needs in the treatment of prevalent dermatological disorders affecting both adults and children. Veradermics' lead product, VDPHL01, is an oral, non-hormonal treatment designed for both men and women suffering from pattern hair loss (PHL), offering a chronic hair loss therapy option. Beyond VDPHL01, Veradermics is developing VDMN, a dissolvable microarray patch technology for the immunotherapy of common warts. The company is also advancing VDAA for the treatment of alopecia areata and VDMC for molluscum contagiosum. These products target a range of conditions, including androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. The company aims to establish itself as a leader in innovative dermatological treatments.

What Products and Services Does MANE Offer?

• Develop novel therapeutics for dermatologic conditions.
• Focus on treatments for pattern hair loss (PHL) in adults and children.
• Offer VDPHL01, an oral, non-hormonal treatment for PHL.
• Develop VDMN, a dissolvable microarray patch for common warts.
• Create VDAA for the treatment of alopecia areata.
• Formulate VDMC for the treatment of molluscum contagiosum.

How Does MANE Make Money?

• Develop and patent novel dermatological therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved products through direct sales or partnerships.

What Industry Does MANE Operate In?

The biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The dermatology market, in particular, is driven by an increasing prevalence of skin conditions and a growing demand for aesthetic treatments. Veradermics, Incorporated operates in this dynamic landscape, competing with both established pharmaceutical companies and emerging biotech firms.

Who Are MANE's Key Customers?

• Healthcare providers (dermatologists, physicians)
• Clinicians treating dermatologic conditions
• Adults and children with dermatologic conditions
• Medical and clinical research community

Return on equity for Veradermics, Incorporated stands at -95.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 59.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.

Veradermics, Incorporated (MANE) Valuation Context

Valued at $4.10B, MANE is classified as a mid-cap stock. Analyst price targets span from $136.00 to $182.00, with a consensus of $162.67. At the current price of $98.14, that implies approximately 66% upside potential. Relative to its peer group, MANE's quantitative score of 62/100 is roughly in line with the peer average of 59/100.

Company Profile

Veradermics, Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Reid Waldman. MANE has traded publicly since 2026.

Veradermics, Incorporated's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Veradermics, Incorporated has beaten Wall Street's EPS estimate in 2 of its last 3 reported quarters — more hits than misses. Reported results have landed about 38.3% below estimates on average.

Wall Street analysts project Veradermics, Incorporated revenue of about $0 for fiscal 2026, with EPS near $-2.85.

MANE Financials

MANE Latest News

MANE Analyst Consensus

MANE MoonshotScore

Veradermics, Incorporated Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources